GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akouos Inc (NAS:AKUS) » Definitions » Earnings per Share (Diluted)

Akouos (Akouos) Earnings per Share (Diluted) : $-2.62 (TTM As of Sep. 2022)


View and export this data going back to 2020. Start your Free Trial

What is Akouos Earnings per Share (Diluted)?

Akouos's Earnings per Share (Diluted) for the three months ended in Sep. 2022 was $-0.54. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 was $-2.62.

Akouos's EPS (Basic) for the three months ended in Sep. 2022 was $-0.54. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2022 was $-2.62.

Akouos's EPS without NRI for the three months ended in Sep. 2022 was $-0.54. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2022 was $-2.62.

During the past 3 years, the average EPS without NRIGrowth Rate was -39.20% per year.

During the past 4 years, Akouos's highest 3-Year average EPS without NRI Growth Rate was -39.20% per year. The lowest was -39.20% per year. And the median was -39.20% per year.


Akouos Earnings per Share (Diluted) Historical Data

The historical data trend for Akouos's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akouos Earnings per Share (Diluted) Chart

Akouos Annual Data
Trend Dec18 Dec19 Dec20 Dec21
Earnings per Share (Diluted)
-0.93 -1.98 -2.77 -2.52

Akouos Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.67 -0.72 -0.78 -0.58 -0.54

Competitive Comparison of Akouos's Earnings per Share (Diluted)

For the Biotechnology subindustry, Akouos's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akouos's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akouos's PE Ratio distribution charts can be found below:

* The bar in red indicates where Akouos's PE Ratio falls into.



Akouos Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Akouos's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2021 is calculated as

Diluted Earnings Per Share (A: Dec. 2021 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-86.671-0)/34.388
=-2.52

Akouos's Earnings Per Share (Diluted) for the quarter that ended in Sep. 2022 is calculated as

Diluted Earnings Per Share (Q: Sep. 2022 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-19.839-0)/36.906
=-0.54

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Akouos  (NAS:AKUS) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Akouos Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Akouos's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Akouos (Akouos) Business Description

Industry
Traded in Other Exchanges
N/A
Address
645 Summer Street, Suite 200, Boston, MA, USA, 02210
Akouos Inc is a genetic medicine company focused on developing gene therapies that restore, improve, and preserve hearing. The company is involved in developing potential genetic medicines for a variety of inner ear disorders.
Executives
Kearny Acquisition Corp 10 percent owner LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Lilly Eli & Co 10 percent owner LILLY CORPORATE CENTER, DROP CODE 1094, INDIANAPOLIS IN 46285
Jennifer Anne Wellman officer: Chief Operating Officer C/O AKOUOS, INC., 645 SUMMER STREET, SUITE 200, BOSTON MA 02210
Sachiyo Minegishi officer: Chief Financial Officer C/O AKOUOS, INC., 645 SUMMER STREET, SUITE 200, BOSTON MA 02210
5am Ventures V, L.p. 10 percent owner 2200 SAND HILL ROAD, SUITE 110, MENLO PARK CA 94025
Kush Parmar director, 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Carmen Chang 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Maha Katabi 10 percent owner SOFINNOVA INVESTMENTS, 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Sofinnova Venture Partners X, L.p. 10 percent owner 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Pivotal Bioventure Partners Fund I G.p., L.p. 10 percent owner 501 SECOND STREET, SUITE 200, SAN FRANCISCO CA 94107
New Enterprise Associates 16, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Paul Edward Walker 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Heather Preston director, 10 percent owner C/O TPG GLOBAL, LLC, 301 COMMERCE STREET, FORT WORTH TX 76102

Akouos (Akouos) Headlines

From GuruFocus